These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26547678)

  • 1. Treatment of pulmonary embolism.
    Décousus H; Mismetti P; Couturaud F; Ageno W; Bauersachs R
    Presse Med; 2015 Dec; 44(12 Pt 2):e393-9. PubMed ID: 26547678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
    Robertson L; Kesteven P; McCaslin JE
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic Therapy for Venous Thromboembolic Disease.
    Jain A; Cifu AS
    JAMA; 2017 May; 317(19):2008-2009. PubMed ID: 28510665
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
    J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct oral anticoagulants: a guide for daily practice.
    Fontana P; Robert-Ebadi H; Bounameaux H; Boehlen F; Righini M
    Swiss Med Wkly; 2016; 146():w14286. PubMed ID: 26964028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.